Company Overview and News


Add JAZZ
to your dashboard

Headline News

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2017 Update

2017-11-21 seekingalpha
Halvorsen's 13F portfolio value increased from $14.85B to $15.44B. The number of positions increased from 53 to 59. (1331-6)

Astellas faces U.S. probe over patient assistance charity support

2017-11-15 reuters
BOSTON (Reuters) - Astellas Pharma Inc has become the latest company to reveal it has become the subject of a U.S. probe into drugmakers’ financial support of charities offering assistance to Medicare patients seeking help to cover out-of-pocket drug costs. (259-0)

Astellas faces US probe over patient assistance charity support

2017-11-15 channelnewsasia
Astellas Pharma Inc has become the latest company to reveal it has become the subject of a U.S. probe into drugmakers' financial support of charities offering assistance to Medicare patients seeking help to cover out-of-pocket drug costs. (259-0)

Corporate News Blog - RXi Pharma Collaborates with Gustave Roussy, Europe's Leading Cancer Centre

2017-11-15 accesswire
LONDON, UK / ACCESSWIRE / November 15, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for RXi Pharmaceuticals Corp. (NASDAQ: RXII) ("RXi"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=RXII. The Company announced on November 13, 2017, that it has signed a collaborative research agreement with Gustave Roussy to evaluate the potential of RXi's novel sd-rxRNA technology platform for use in cancer treatments. (30-1)

Current Breakdown Of The ROTY Model Account

2017-11-12 seekingalpha
Every so often I like to break down our current holdings in the ROTY model account. (84-0)

ROTY Edition 1 Volume 49: Updates From Quarterly Calls And Trades

2017-11-10 seekingalpha
I remind readers of the need to review quarterly results, filings, and conference calls to monitor changes with their stock holdings. (113-0)

Jazz Pharmaceuticals, Inc. 2017 Q3 - Results - Earnings Call Slides

2017-11-08 seekingalpha
The following slide deck was published by Jazz Pharmaceuticals, Inc. in conjunction with their 2017 Q3 earnings call. (3-0)

Airline Stock Roundup: LUV & ALK Expansion Update, DAL October Traffic Report

2017-11-08 zacks
The last week saw key airline players like Southwest Airlines (LUV - Free Report) and Alaska Air Group’s (ALK - Free Report) subsidiary — Alaska Airlines — revealing updates on their intention to add additional flights in a bid to expand their presence. (46-0)

AmTrust to Transfer Majority of U.S.-Based Fee Businesses

2017-11-08 zacks
AmTrust Financial Services, Inc. (AFSI - Free Report) inked a deal with Madison Dearborn Partners (“MDP”) to transfer 51% equity stake of its U.S.-based fee businesses to the latter. The business is valued at $1.15 billion, plus up to an additional $50 million subject to conditions. The transaction is expected to close in the first half of 2018. It positions the fee business for accelerated growth. (32-0)

Jazz Pharmaceuticals (JAZZ) Q3 Earnings Top, 2017 View Cut

2017-11-08 zacks
Jazz Pharmaceuticals Public Limited Company (JAZZ - Free Report) reported third-quarter 2017 adjusted earnings of $3.22 per share, beating the Zacks Consensus Estimate of $2.89. The bottom line also increased 23% from the year-ago figure. (61-0)

Jazz Pharmaceuticals Plc (JAZZ) Q3 2017 Results - Earnings Call Transcript

2017-11-08 seekingalpha
Welcome to the Jazz Pharmaceuticals Third Quarter 2017 Earnings Conference Call. Following an introduction from the company, we will open the call to questions. (3-0)

Otonomy's $525 Million Dive Is Fennec's Good Fortune

2017-11-02 seekingalpha
Over the last six months, Fennec has uplisted, raised $7.6M above market, and released positive Phase 3 data. (102-5)

GlycoMimetics: ASH Update

2017-11-02 seekingalpha
I reiterate that while GlycoMimetics's shelf offering might have caused weakness in the share price, comparisons to Celator lead me to believe the stock is heavily undervalued. (263-1)

Adamas Pharmaceuticals, Inc.: Substantial Upside For A Misunderstood Drug Maker

2017-11-01 seekingalpha
We believe Adamas’s lead drug Gocovri will achieve blockbuster status, while its earlier-stage pipeline assets alone are worth billions. (58-0)

Marinus Pharmaceuticals: The Next Big Thing In CNS

2017-10-31 seekingalpha
Orphan drug designation, paired with unprecedented data, enables expedited approval of Ganaxolone in CDKL5 and additional orphan pediatric indications. (165-2)

CUSIP: G50871105